Ocular Therapeutix Inc.'s phase III trial of OTX-TP (travoprost), a sustained-release punctal plug for glaucoma and ocular hypertension, failed to meet its primary endpoint, but it also reached what it called a "statistically significant" reduction of intraocular pressure vs. placebo at eight of nine prespecified time points.